Verrica Pharmaceuticals Inc. (VRCA) Tops Q4 EPS by 5c

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) reported Q4 EPS of ($0.53), $0.05 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $1.98 million versus the consensus estimate of $941.92 thousand.

For earnings history and earnings-related data on Verrica Pharmaceuticals Inc. (VRCA) click here.

You May Also Be Interested In

• Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
• Kustom Entertainment agrees to buy Tickets For Less operator TFL
• Why UBS thinks this European chipmaker is still undervalued despite its premium valuation